ADDF-Harrington Scholar Program
Forecasted
ADDF-Harrington Scholar Program supports academic researchers with drug-development funding and expert guidance to advance novel medicines that treat, prevent, slow, or reverse Alzheimer’s and related dementias.
Funder: Alzheimer's Drug Discovery Foundation
Due Dates (Anticipated): June 2027 (Letter of Intent) | August 2027 (Full proposal)
Funding Amounts: Up to $600,000 over two years, plus tailored drug-development support
Summary: Supports academic drug-development projects advancing novel medicines for Alzheimer’s disease and related dementias.
Key Information: Funding is provided through mission-related investments requiring returns based on scientific and/or business milestones.
Description
The ADDF-Harrington Scholar Program is a collaboration between the Alzheimer’s Drug Discovery Foundation (ADDF) and the Brain Health Medicines Centers of the Harrington Discovery Institute. It advances academic discoveries into medicines that treat, prevent, slow, or reverse Alzheimer’s disease and related dementias. Support covers milestone-driven drug development from hit-to-lead optimization through investigational new drug (IND)-enabling studies.
The program combines funding with project-specific guidance from pharmaceutical industry experts in medicinal chemistry, pharmacology, toxicology, and business development. It prioritizes emerging therapeutic targets, particularly proteostasis and senescence, and targets with clear measures of target engagement. Supported modalities include small molecules, antibodies, peptides, oligonucleotides, and gene therapies. Researchers developing relevant drugs outside the Alzheimer’s field are strongly encouraged to apply.
